Exelixis Stock News

Exelixis (NASDAQ:EXEL) had its price target raised by Oppenheimer from $33.00 to $37.00 in a report published on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the biotech

In a report released today, Chad Messer from Needham assigned a Buy rating to Exelixis (EXEL – Research Report), with

Exelixis, Inc. (NASDAQ: EXEL) today announced positive phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizum

Stifel Financial Corp reduced its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 2.4% in the 2nd quarter, HoldingsChannel reports. The firm owned 98,760 shares of the biotechnology company’s

Opdivo in Combination with CABOMETYX Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma....

Glenmede Trust Co. NA increased its position in Exelixis, Inc. (NASDAQ:EXEL) by 1,036.0% in the second quarter, HoldingsChannel.com reports. The fund owned 25,242 shares of the biotechnology company�

Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics today announced new preclinical data that support the continued development of ICON-2, an ADC co

Regulatory News: Ipsen (Euronext : IPN ; ADR : IPSEY) a annoncé aujourd’hui que de nouvelles données d’essais cliniques et en vie réelle concernant di

The long-term picture is bright for these healthcare stocks thanks to stable product revenue.

Exelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug

The highly defensive healthcare sector is a smart place to park your cash when volatility picks up.

Exelixis, Inc. (NASDAQ:EXEL) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FD

These high-growth stocks look to be slam dunks for long-term investors.